Elodie Bousquet, MD, PhD, and international researchers studied type 3 macular neovascularization (T3 MNV) using optical coherence tomography. In 64.5% of 31 eyes with T3 MNV, it developed over soft drusen, showing drusen growth and outer layer thinning before T3 MNV.
Massachusetts Eye and Ear researchers came up with a mobile app called All_Aboard, designed to be used along with mainstream GPS systems and focuses on improving micro-navigation.
Baruch Kuppermann, MD, PhD, discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular edema and retinal vein occlusion.
Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab, respectively, in branch retinal vein occlusion and central retinal vein occlusion.
A minimum of 5,000 patients with up to 5 years of follow-up will be included in the study, with patients from a variety of practice settings and clinician experiences in 28 countries and 500 sites
Jennifer I. Lim, MD, FARVO, FASRS sat down with Hattie Hayes of Ophthalmology Times Europe to discuss her findings, including exciting advancements in targeting Ang2 and VEGF from the Angiogenesis Exudation and Degeneration 2024 event.
Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.
Carl D. Regillo, MD, FACS, FASRS, discussed recent data from the DAVIO 2 trial in his presentation at the virtual Angiogenesis, Exudation, and Degeneration 2024.
Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).
Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.
Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.
SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.
Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.
Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA
Under the terms of the agreement, Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialize KIO-301 for the treatment of inherited retinal diseases in a deal valued at up to $301 million.
A new study out of Guangzhou, China found that individuals younger than 18 years of age and experiencing high myopia are at a high risk of progressively worsening myopic maculopathy.
The agreement settles Zeiss’s lawsuit against Topcon’s U.S.-based subsidiaries that had been set to start this month in U.S. federal court for the Northern District of California.
In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.
According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.
A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.
Wilmer's expansive focus and deep bench are advancing the understanding of artificial intelligence tools and potential ophthalmic applications.
The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.
Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.
Researchers at Mass Eye and Ear have demonstrated that retinal imaging can help predict a person’s risk of developing ocular, neuropsychiatric, cardiac, metabolic, and pulmonary diseases.
Joshua Mali, MD, offers up his predictions for ophthalmology in 2024.
LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.
ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.
Ophthalmologist shares pearls from recent roundtable discussion on topic.
David Hutton of Ophthalmology Times talks with Jeffrey Cleland, PhD, President and CEO of Ashvattha Therapeutics, about the company's D-4517.2, a unique nanomedicine technology for the treatment of wet AMD and DME.
.png "Optometry Times"){kind=logo}
